OA1 (GPR143; GPCR, G-protein-coupled receptor), the protein product of the ocular albinism type 1 gene, encodes a pigment-cell-specific GPCR that localizes intracellularly to melanosomes. OA1 mutations result in ocular albinism due to alterations in melanosome formation, suggesting that OA1 is a key player in the biogenesis of melanosomes. To address the function of OA1 in melanosome biogenesis, we have used siRNA inactivation and combined morphological and biochemical methods to investigate melanosome ultrastructure, melanosomal protein localization and expression in human pigmented melanocytic cells. OA1 loss of function leads to decreased pigmentation and causes formation of enlarged aberrant premelanosomes harboring disorganized fibrillar structures and displaying proteins of mature melanosomes and lysosomes at their membrane. Moreover, we show that OA1 interacts biochemically with the premelanosomal protein MART-1. Inactivation of MART-1 by siRNA leads to a decreased stability of OA1 and is accompanied by similar defects in premelanosome biogenesis and composition. These data show for the first time that melanosome composition and identity are regulated at early stages by OA1 and that MART-1 likely acts as an escort protein for this GPCR.
INTRODUCTION
Albinism comprises a heterogeneous group of inherited genetic disorders characterized by a variable loss of pigmentation in the eye, hair or skin. Ocular albinism type 1 (OA1) is an X-linked disorder that, different from other forms of albinisms, is not caused by impairment of melanin production but by reduced number of melanosomes (1) , the organelles in which melanin is synthesized and stored in retinal pigment epithelium (RPE) and skin melanocytes. Mutations in OA1 gene also induce formation of aberrant 'giant' melanosomes, called macromelanosomes (2) . Thus, this form of albinism appears to be caused by a defect in melanosome organellogenesis. The protein product of the OA1 gene is a pigment cell-specific G-protein-coupled receptor (GPCR) (3 -5) , whose ligand L-DOPA was recently identified (6) . Differently from canonical GPCR, OA1 preferentially localizes to intracellular compartments such as melanosomes and lysosomes, where it can signal from the organelle lumen to the cytosol (4, 7) . Although the genetic defect was reported more than 10 years ago (8) , how OA1 functions to control melanosome biogenesis has remained enigmatic, frustrating efforts toward development of new therapeutic strategies for ocular albinism.
Melanosomes are lysosome-related organelles that are distinct from conventional lysosomes within pigment cells (9, 10) . Melanosomes develop through sequential maturation stages that can be defined on the basis of morphology and that are enriched in a specific set of protein components (9, 11) .
Stage I and II melanosomes are characterized by the presence of intralumenal fibrillar sheets (12 -14) , in which the major component is the fibrillogenic protein Pmel17 (13, (15) (16) (17) , but lack melanogenic enzymes such as tyrosinase and tyrosinase-related proteins. Deposition of black melanin along the fibers is initiated in stage III melanosomes as a consequence of the delivery of melanogenic enzymes to preformed stage II melanosomes. Once formed, the mature stage IV melanosomes are transported to the cell periphery for transfer to neighboring keratinocytes or stored within the RPE (18, 19) .
Stage I premelanosomes correspond to early endosomal vacuoles that serve as intermediates for cargo bound both for lysosomes and melanosomes at different stages (9) . As a first step toward melanosome formation, the transmembrane protein Pmel17 is sorted to intraluminal vesicles (ILVs) of endosomes called multivesicular bodies (MVBs) (9, 15, 16) . Concomitant with the sequestration in ILVs, Pmel17 is cleaved by a mechanism involving a prohormone convertase liberating a fibrillogenic fragment (Ma) in its lumenal domain, which leads to the generation of the non-membranous amyloid-like fibrillar structures (14, 16, 20) . Sorting of transmembrane proteins such as the epidermal growth factor receptor to ILVs of MVBs requires ubiquitylation and the sequential recruitment of four multimeric complexes, the so-called ESCRT (endosomal sorting complex required for transport) machinery composed of ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III (21) . Whereas sorting of Pmel17 appears to be independent of ubiquitylation and of the ESCRT-0/ESCRT-I machinery (22) , sorting of another melanosomal protein, MART-1 (MLANA), which is similarly sequestered in ILVs of MVBs, appears to require ubiquitylation (23, 24) and ESCRT proteins (22, 25) . MART-1 has been reported to interact with Pmel17 (26) , but the function of MART-1 in melanogenesis is not well understood.
In this study, we investigated the role of OA1 in melanosome biogenesis, addressing its intracellular localization and how loss of function may alter trafficking steps required for melanosome maturation. In addition, we investigated how it may exert its role together with other melanosomal proteins. Using a combination of light and electron microscopy (EM) and biochemical methods, we show that OA1 controls the generation of premelanosomes and that it cooperates with MART-1 for this function. Altogether, our data suggest that OA1 functions together with MART-1 to maintain melanosome composition and identity within the endocytic system.
RESULTS

OA1 localizes to immature and mature melanosomes
Previous studies have addressed the subcellular localization of endogenous OA1 or GFP-tagged recombinant OA1 in melanocytic cells (4, 7, 27) , but its localization within the distinct melanosomal stages and/or endosomes and lysosomes was not completely resolved. To qualitatively and quantitatively evaluate the subcellular distribution of the endogenous OA1 protein in the melanocytic cell line MNT-1, we have used immunogold labeling on ultrathin cryosections (IEM). MNT-1 cells resemble untransformed skin melanocytes by expression of mRNAs encoding melanogenic proteins (28) and by ultrastructure, presenting melanosomes at all four stages (9) . We have also investigated the localization of recombinant OA1 protein (OA1-Flag or OA1-EGFP) in transfected MNT-1 cells (see what follows; Supplementary Material, Fig. S1 ) and in mouse melan-a immortalized melanocytes (data not shown). Consistent with previous studies, OA1 was detected at the limiting membrane of a small cohort of pigmented melanosomes labeled for the melanosomal enzyme Tyrp1 (stage III -IV) ( Fig. 1A, arrows ). Within these mature pigmented melanosomes, OA1 was often associated with small ILVs (Fig. 1A , arrowhead) and was also present at the membrane of cytoplasmic vesicles often located in close proximity to melanosomes ( Fig. 1B, arrowhead) . OA1 was detected at the limiting membrane of lysosomes ( Fig. 1E , arrows) and in ILVs of late endosomes/MVBs (Fig. 1E , arrowheads). In agreement with its association with ILVs of MVBs, and like other ILV-associated membrane proteins such as CD63, OA1 was detected in extracellular exosomes (not shown) which correspond to ILVs secreted upon fusion of MVBs with the plasma membrane (29) . Although OA1 appeared broadly distributed, our observations revealed that the bulk was localized to organelles highly labeled for Pmel17 ( Fig. 1C and D, arrows; see quantification in Fig. 1F ) that correspond to stage I and stage II premelanosomes (9) . This is consistent with, but extends quantitatively, the observations reported previously (3, 7) . Similar to endogenous OA1, the recombinant transfected proteins (OA1-Flag or OA1-EGFP) localize to the distinct melanosomal stages and to lysosomes. However, compared with the endogenous protein, we observed a shift in the localization of OA1 toward more mature melanosomes (Supplementary Material, Fig. S1A and B, arrows). We also observed that cells expressing higher levels of OA1 were characterized by the presence of large electron-lucent OA1-positive membrane vesicles (350 nm). These vesicular structures were also labeled for Tyrp1 and often localized in close proximity to melanosomes in both human (Supplementary Material, Fig. S1A , asterisks) and mouse cells (data not shown). These vesicles were possibly induced by the overexpression of OA1 since they were not observed in Flag/EGFP empty vector-transfected cells (data not shown). The observed phenotype indicates that the trafficking of recombinant OA1 may not fully reflect that of the endogenous protein. However, on the other hand, it also suggests a dominant negative effect of OA1 expression that may result in the accumulation of transport intermediates whose trafficking may be controlled by OA1.
Altogether, these data show that OA1 is widely distributed throughout the endo-melanosomal system but that most of endogenous protein is localized in unpigmented stage II melanosomes. This finding is in agreement with the suggested function for OA1 at early stages of melanogenesis as we proposed previously (1) .
OA1 loss of function affects melanosomal protein trafficking and melanosome size at early stages of biogenesis
To get further insights into the function of OA1, we inactivated OA1 by RNAi in pigmented MNT-1 cells and analyzed melanosome morphology and composition right after the loss of OA1 activity. This approach overcomes the limits and/or Human Molecular Genetics, 2009, Vol. 18, No. 23 4531 I, stage I; II, stage II; III, stage III; IV, stage IV; I/II, stage I/II compensations of immortalized melanocytes from OA1 patients or mice that contain primarily mature organelles and preclude the study of the different sequential events leading to the formation of macromelanosomes. We tested three oligonucleotides targeting three different regions of the human OA1 mRNA, and a non-targeting siRNA as a control (Ctrl). Two of them efficiently decreased the levels of OA1 transcripts (15% siRNA 1, 78% siRNA 2, 95% siRNA 3) ( Fig. 2A ). Downregulation of endogenous OA1 protein was confirmed by western blot and immunofluorescence ( Fig. 2B -D) . In siOA1 MNT-1 cells, mature melanosomes and melanin content cells were reduced as much as 50% compared with the control ( Fig. 2E-G) . Analysis at the ultrastructural level, by conventional EM, revealed a reduction of the total number of melanosomes in MNT-1 cells depleted of OA1 ( Fig. 2H -K) , consistent with the phenotype characterized in ocular albinism mouse model and patients. Although we do not observe the 'classical' pigmented macromelanosomes, OA1-depleted MNT-1 cells harbor, in addition to normal-sized melanosomes, abnormally enlarged organelles with a heterogeneous content and could possibly correspond to the precursors of the macromelanosomes ( Fig. 2I ; Supplementary Material, Fig. S2A ). These aberrant mixed compartments contain Pmel17-positive fibrils characteristic of immature melanosomes and an electron dense core of melanin ( Fig. 2I , asterisk; Supplementary Material, Fig. S2B and C). Similar phenotypes were observed with both siRNA sequences (siRNA 2 and 3) excluding that the phenotype derives from mistargeting. Of note, similar enlarged 'mixed' organelles were also observed in OA1 in vitro-cultured melanocytes from knockout mouse (melan-Oa1 2/2 ) ( Fig. S2D and E). OA1-depleted cells also harbored enlarged immature unpigmented melanosomes that had lost the typical striated appearance and whose internal fibrils were clearly disorganized ( Fig Fig. S2A ). In order to investigate whether these morphological alterations were accompanied by a defect in the localization of melanosomal proteins, we analyzed the distribution of melanosomal proteins in siOA1targeted cells by IEM. The fibrillar structures apposed to or contained within the abnormal melanosomal structures were highly labeled with an antibody directed against Pmel17, the major component of the fibrils (Fig. 3B , arrowhead; Supplementary Material, Fig. S2C , arrows). Interestingly, Tyrp1, which is nearly absent from Pmel17-enriched stage II premelanosomes in control cells, is detected at high levels at the membrane of the enlarged organelles ( Fig. 3A and B, arrows; see also Fig. 3F ), suggesting an alteration of its trafficking upon OA1 depletion. Another protein that also appeared to be mislocalized to the enlarged melanosomal organelles is LAMP1. LAMP1 is a lysosomal membrane protein that is present only in small amounts at the membrane of Tyrp1-positive melanosomes ((9) and Fig. 3C and E, arrows). In contrast, in OA1-depleted cells, LAMP1 was abundant in both aberrant, enlarged pigmented organelles and normal size melanosomes (Fig. 3D , F and G, arrows). Quantification of these observations is shown in Table 1 . LAMP1 also accumulated in Tyrp1-positive vacuolar structures ( Fig. 3H , inset) that were reminiscent of the vesicles observed upon OA1-Flag overexpression (Supplementary Material, Fig. S1 ), suggesting that depletion of OA1 or a dominantnegative effect may lead to similar phenotypes. It also suggests that OA1 may function at a fusion/fission step regulating Tyrp1 and LAMP1 content of melanosomes. Although the melanin content was generally reduced in OA1-depleted cells, western blot experiments performed in these cells revealed a slight increase of the amount of Tyrp1 and no significant differences in the amount of LAMP1 ( Fig. 3I ), consistent with a defect in their trafficking and not expression/ degradation of these proteins. To get further insight into the trafficking defects and nature of the organelles affected upon OA1 loss of function, we performed IEM on cells that were allowed to internalize transferrin (to load early-recycling endosomes), BSA gold (to load endo-lysosomal compartments) or that were incubated with the weak base DAMP, to evaluate the acidity of the organelles (9) . Transferrin (data not shown) and the endocytic tracer BSA-gold (BSAG) were not detected in the enlarged organelles (Supplementary Material, Fig. S3A and B) and vacuoles (data not shown), indicating that the defects in trafficking and organelle biogenesis caused by OA1 loss of function were not due to aberrant mistargeting within the endosomal system. The enlarged melanosomal organelles appeared to be acidic as are premelanosomes in wild-type cells as assayed with DAMP (9) (Supplementary Material, Fig. S3C and D). However, and despite that DAMP accumulation is not a quantitative assay for pH, these organelles show an increased labeling for the radical DNP (Supplementary Material, Fig. S3D ), suggesting that they may be slightly more acidic.
OA1 and MART-1 loss of function similarly affect Pmel17 final processing and early melanosome biogenesis
We next aimed at further investigating how premelanosome biogenesis could be affected by the loss of OA1 function. The major biogenetic component of the stage II fibrils is the pigment cell-specific protein Pmel17. In stage II melanosomes, the Pmel17 forms are detectable with HMB45 antibody, which recognizes the Ma fragment and its proteolytic products (30) (31) (32) , and with Pep13h antibody, recognizing the processed full-length (P1, 100 kDa) and the cleaved forms (Mb, 26 kDa; CTF, 10 kDa) (33) .
Enlarged organelles displayed disorganized fibrils and this prompted us to evaluate Pmel17 expression and processing. We did not detect significant changes of Pmel17 transcript levels upon OA1 inactivation (Supplementary Material, Fig. S4A ). Next, we analyzed the different maturation forms of Pmel17 by using HMB45 and Pep13h antibodies. Although Pep13h did not reveal significant differences in the levels of P1 and Mb ( Fig. 4Ac ; Supplementary Material, Fig. S4Bb ), an accumulation of Ma fragment (80 kDa) and a reduction of one of its subproducts (MaC, 35 kDa) were observed with the HMB45 antibody in both the TX-soluble ( Fig. 4Aa ) and TX-insoluble pool ( Fig. 4Ab ; Supplementary Material, Fig. S4Ba ) of siOA1 cell lysates (Fig. 4A ). The TX-insoluble pool is enriched in amyloid fibers that are insoluble in nondenaturing detergent TX100 (16) . Since MaC is considered to be the major form of the HMB45-reactive species within the fibers (31,32), its reduction is likely to reflect the disorganization of amyloid-like fibers observed in stage II Human Molecular Genetics, 2009, Vol. 18, No. 23 4533 These results indicate that although Pmel17 appears to be cleaved in its luminal domain, its final processing to form the MaC fragment is impaired consistent with the altered morphology of the intraluminal fribillar contents of the premelanosomal compartment. Such effects observed upon OA1 depletion were reminiscent of those described in cells that do not express MART-1 (26) . MART-1 is an integral membrane melanosomal protein that has been shown to form complexes with Pmel17 and has been suggested to control Pmel17 processing and stability (26) . We therefore used siRNA to deplete MART-1 from MNT-1 cells. MART-1 was effectively downregulated (reduction of 90% of detectable MART-1 transcript and protein) (Figs 4B and 6I). We confirmed that Pmel17 maturation was affected in MART-1-depleted cells. In particular, similar to OA1 knockdown, we detected accumulation of the Ma fibrillogenic fragment accompanied by a reduction of its subproduct MaC (Fig. 4B ). To better define the compartments affected by MART-1 depletion, we performed immunogold EM analysis on ultrathin cryosections of siMART-1-treated cells. No normal stage I premelanosomes were found, but we noted the presence of many aberrant enlarged compartments that often displayed a mixed content of fibrils and electron dense pigment, similar to those observed in siOA1 cells ( Fig. 4D ). Interestingly, these compartments contained abnormally large ILVs, and their Pmel17-positive fibers were disorganized and/or apposed to one or both sides, indicating altered early melanogenesis. We also found that Tyrp1 ( Fig. 4E and F, arrows) and LAMP1 (data not shown) accumulated in early Pmel17-positive premelanosomal compartments with concomitant reduction at the melanosomal membrane compared with control cells.
Overall, these observations show that loss of function of either OA1 or MART-1 leads to an impairment of melanosome biogenesis at its earliest steps and to mistrafficking of distinct melanosomal proteins likely en route to their final destination, in this case lysosomes or melanosomes. Moreover, these results show that MART-1, similar to OA1, regulates melanosome maturation and in particular the maintenance of melanosomal identity and composition.
MART-1 interacts with OA1 and is required for OA1 stability in MNT-1 cells
On the basis of the data presented so far, we hypothesize that either OA1 and MART-1 fulfill a similar redundant function in early melanogenesis or that one of the two proteins affects the function of the other. We thereby evaluated possible interactions between these proteins and investigated the consequences of MART-1 loss of function on OA1 expression and localization.
For this purpose, we immunoprecipitated endogenous OA1 from MNT-1 extracts and tested for the presence of MART-1 by immunoblotting. Consistent with our hypothesis, the 18 kDa form of MART-1, corresponding to the notubiquitylated form (24) , was detected in the anti-OA1 immunocomplexes ( Fig. 5A) . We confirmed the specificity of this interaction by co-immunoprecipitation of OA1 with Galpha-i3 (data not shown), as already published (4), but not with the melanogenic enzyme Tyrp1 (Fig. 5A ). Although we detected a biochemical interaction between OA1 and MART-1, co-localization, as analyzed by immunofluorescence followed by 3D deconvolution or IEM, was limited to only a small subset of cellular compartments ( Fig. 5B -L). OA1 was distributed in vesicular structures that mainly correspond to immature and mature melanosomes ( Fig. 1 ), but MART-1 was essentially localized in the perinuclear area in a region that mainly corresponds to the Golgi/TGN and post-Golgi endosomal compartments ( Fig. 5B -I and J). These data were confirmed by IEM, in which OA1 and MART-1 were detected together only within the Golgi apparatus, vesicles close to the Golgi and endosomal compartments ( Fig. 5J -L, arrows).
Interestingly, when we analyzed cell lysates from MART-1depleted cells, we found that OA1 protein expression and distribution were severely affected ( Fig. 6E-H and J). The levels of OA1 protein was greatly reduced but not its transcript (Fig. 6I ). In contrast, both MART-1 RNA and protein levels were not affected in the absence of functional OA1 (Supplementary Material, Fig. S4A and C). These observations suggested that MART-1 loss of function induces an increased degradation of OA1. To further test this hypothesis and to shed light on the mechanisms involved in its decreased expression/stability, MART-1-depleted cells were treated for 5 h with drugs known to inhibit lysosomal (chloroquine) or proteasomal degradation (MG132 or epoxomycin), respectively. Chloroquine is an inhibitor of intra-lysosome catabolism that raises intralysosomal pH disrupting the activity of lysosomal acid hydrolases (34, 35) . As analyzed by western blot, in control cells treated with chloroquine, the levels of OA1 increased after 5 h of treatment, showing that OA1 generally undergoes a lysosomal degradation. A similar increase of OA1 protein levels was observed in chloroquine-treated MART-1-depleted cells (Fig. 6Ka) , showing a partial rescue of OA1 protein levels after 5 h of treatment. Since proteasomes have also been shown to be involved in later steps of lysosomal transport and lysosomal degradation of membrane proteins (36), MART-1-depleted cells were treated with the proteasome inhibitors MG132 or epoxomycin. MG132 is a widely used potent synthetic inhibitor of a number of proteasome-associated proteases (37, 38) . Epoxomycin is a natural proteasome inhibitor specific for the 20S proteasome (39) . OA1 protein levels were slightly higher in treated versus untreated control cells ( Fig. 6Kb and c) . 
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In siMART-1 cells, we observed significantly higher levels of OA1 protein after 5 h of incubation with proteasome inhibitors compared with the untreated cells ( Fig. 6Kb and c) . These results suggest that the degradation of OA1 that is increased upon MART-1 depletion is also dependent on proteasomal activity. The stronger effect of MG132 compared with epoxomycin could be due to the fact that this compound is not specific for proteasome and is also a potent inhibitor of various cysteine proteases and cathepsins acting in lysosomes (40, 41) . Overall, these data show that OA1 stability/expression requires MART-1 and that in the absence of MART-1, OA1 undergoes degradation requiring lysosomal and proteasomal activity.
DISCUSSION
Melanosomes represent a class of lysosome-related organelles that coexist with late endosomes and lysosomes within melanocytes and RPE. The pathways by which melanosomal proteins are diverted from the classical endocytic organelles toward melanosomes and/or differentially targeted to different melanosomal stages are incompletely defined, but are disrupted in several genetic diseases (42) . These diseases, leading to defects in melanosome biogenesis and transfer, are due to mutations in genes encoding proteins involved in intracellular trafficking but also mutations in melanosomespecific proteins whose functions remain so far unclear (10, 42) . We show here that the GPCR OA1 functions early in melanosome biogenesis controlling not only melanosome size but also melanosome composition, and thereby appropriate maturation. In addition, we show that OA1 stability and function are ensured by its interaction with the premelanosomal protein MART-1, assigning a significant role to this protein in melanosome biogenesis.
OA1 functions in early melanogenesis and melanosome composition
Our studies evidence that the bulk of intracellular OA1 localizes to Pmel17-positive unpigmented premelanosomes. The presence of endogenous OA1 in the precursors of premelanosomes, which also display other melanosomal proteins such as Pmel17 and MART-1 (9, 23, 43) , suggests a function for this GPCR early in melanogenesis as predicted previously on the basis of our genetic studies (1) . The albinism phenotype caused by OA1 loss of function is characterized not only by the presence of macromelanosomes but also by a reduction in melanin content and the number of melanosomes at early stages of their maturation (1, 44) . After 5 days of OA1 inactivation, we were able to reproduce the defect in melanosome number but not the 'classical' macromelanosome phenotype probably because a longer time is required to complete melanosome maturation. However, even after short inactivation (3 -5 days), we observed abnormal enlarged pigmented structures with a heterogeneous content. These structures display a size similar to macromelanosomes with an average diameter of 0.9-1 mm (1). In addition, several of the enlarged compartments observed in OA1 knocked-down cells, although not fully electron denselike macromelanosomes in melanocytes from OA1 mutant mice, display a mixed content with an 'amorphous' melanin core and fibrillar sheets ((2) and Supplementary Material, Fig. S2B -E) . For all these reasons, we believe that the enlarged structures observed in siOA1 cells correspond to the precursors of macromelanosomes. These aberrant compartments could result from fusion of anomalous premelanosomes with mature melanosomes. Otherwise and not mutually exclusive, these compartments could also arise from an improper formation/composition of immature stage II melanosomes resulting from abnormal fusion of transport intermediatesor from lack of retrieval of membranes from maturing melanosomes-to remove cargoes like LAMP1. This is supported by our observations that OA1-depleted cells accumulate Tyrp1-containing vesicular structures and that immature melanosomes (stages I-II) displayed consistent amounts of Tyrp1 at their limiting and internal membranes. This melanogenic enzyme is, in general, absent from stage I/stage II unpigmented melanosomes and enriched in pigmented stage III and stage IV (9) . These observations indicate mistargeting of melanogenic enzymes to immature melanosomes and this event may lead to abnormal pigment synthesis within premelanosomal compartments. These observations can also explain the reduced number of early stage melanosomes observed in OA1 mutant RPE (1). Abnormal protein targeting is not limited to melanogenic enzymes but also to proteins of other cellular organelles such as the lysosomal membrane protein LAMP1. LAMP1 is normally present in lysosomes; it is also detectable at lower amounts in mature melanosomes but absent from immature unpigmented melanosomes (9) . The presence of Tyrp1 and LAMP1 in vesicular structures and within Pmel17-positive early melanosomes favors the hypothesis of an 'aberrant' fusion of LAMP1 and Tyrp1-loaded vesicles with stage I/stage II premelanosomes. The nature of the Tyrp1/LAMP1 containing transport intermediates is not totally clear. On the basis of our recent studies, they most likely correspond to endosomal compartments that are required intermediates for Tyrp1 transport from the Golgi to the limiting membrane of melanosomes (25) . The vacuolar structures observed upon OA1 inactivation show similar characteristics, containing both Tyrp1 and LAMP1 but not internalized transferrin (data not shown) or the endocytic tracer BSAG. This is consistent with the notion that these are post-Golgi/endosomal intermediates that are placed downstream of the sorting decision point to segregate endosomal from melanosomal cargo. Similar vesicular structures bearing OA1 at their membrane were observed in OA1overexpressing cells, supporting our hypothesis that OA1 is involved in regulating trafficking of such intermediates. One plausible hypothesis is that OA1 controls their transport/ fusion to/with melanosomes. Since we detected the bulk of endogeneous OA1 in immature melanosomes, OA1 possibly functions in these compartments to negatively control a 'too early' fusion of transport intermediates before complete maturation of stage II premelanosomes. In the absence of functional OA1, these transport intermediates aberrantly fuse with immature melanosomal compartments, leading to mistargeting of these proteins to their membranes before completion of maturation. Thereby, it seems plausible that in melanocytes issued from OA1 mutant mice, pigmented melanosomes rather correspond to immature aberrant organelles, with an inappropriate composition leading to synthesis of melanin pigments in the wrong organelle. This explains the morphological features of 
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OA1 and MART-1 similarly influence Pmel17 processing and melanosome maturation
The enlarged premelanosomal compartments harboring Tyrp1 and LAMP1 at their limiting membrane display Pmel17positive fibrils in their lumen although the fibrils do not appear to be fully organized as in classical stage II premelanosomes (9) . The premelanosomal protein Pmel17 is properly processed as judged by western blotting and is able to generate fibrils, indicating that its cleavage by prohormone convertases is not affected in the absence of functional OA1. However, we observed an increased amount of the Ma fragment over MaC, indicating that one very last step of its processing required for fibril formation is impaired, resulting in abnormally assembled fibrils. The cause of the observed alterations in fibril formation/organization remains unclear. The intralumenal acidification of the aberrant organelles, as assayed with the weak-base DAMP, does not appear to be significantly altered compared with control unpigmented premelanosomes. However, we cannot exclude that the slightly higher labeling observed in the inactivated cells could be due to a defective de-acidification required to progress the formation of the fibrils. Otherwise, the inefficient processing could also be the consequence of an altered trafficking of the enzymes required for these last steps of Pmel17 processing. Testing this hypothesis requires further identification of the enzymes involved in Pmel processing. Although some of the enzymes involved in early steps of Pmel17 processing have been at least partially identified (16, 33) , those allowing these final steps of cleavage are still unknown. Interestingly, a similar alteration of Pmel17 processing was observed in cells in which the premelanosomal protein MART-1 was inactivated. MART-1 has been suggested to control Pmel17 expression, stability, trafficking and processing (26) . We show here that in cells in which MART-1 expression was reduced by 90%, Pmel17 processing is affected but not its expression and trafficking. MNT-1 cells show only a partial phenotype of that observed in primary human melanocytes and SK-MEL-28 cells (26); however, we confirmed the functional relevance of MART-1 in the generation of Pmel17 Ma fragment. In this study, we also unraveled a morphological phenotype in MART-1 knocked-down cells: enlarged aberrant premelanosomes with disorganized fibrils and mistargeting of Tyrp1 and LAMP1 to Pmel17positive organelles. These vesicles are similar to those observed in OA1-depleted cells. Moreover and despite the higher enrichment in premelanosomes, OA1 such as the premelanosomal protein MART-1 is broadly distributed throughout the biosynthetic pathway, mature melanosomes and lysosomes. Interestingly, in a manner similar to the overexpressed OA1 in human and mouse melanocytes (our study), the ubiquitylation-deficient MART-1 mutant is mistargeted to mature melanosomes (24) . We, therefore, hypothesized that OA1 and MART-1 could function at a similar step and/ or reciprocally regulate each other.
OA1 expression and function requires MART-1 as an escort protein
Our observations are consistent with the hypothesis that MART-1 is an essential regulator of OA1 expression and function. These two proteins interact biochemically, as shown by co-immunoprecipitation, and this interaction appears to be independent of the reported MART-1/Pmel17 interaction (26) since we did not observe co-immunoprecipitation of OA1 with Pmel17 (data not shown). MART-1 may function in the biosynthetic transport/stabilization of OA1 and this indicates that the phenotypes observed in MART1-depleted cells could rather be the consequence of a decreased expression/function of OA1. In the absence of OA1, MART-1 expression was not affected at the RNA and protein levels. In the absence of functional MART-1, OA1 expression was not affected at the RNA level but significantly decreased at the protein level as assayed by western blot and immunofluorescence. We show that OA1 expression can be restored in the presence of lysosomal and proteasomal inhibitors. These results indicate that similar to other transmembrane proteins (36, 46, 47) including other GPCRs (48, 49) , OA1 degradation requires lysosomal and proteasomal activity. Although these proteins do not appear to be proteasome substrates, their lysosomal degradation is blocked by proteasomal inhibitors. How proteasomes regulate OA1 transport to the lysosome and lysosomal degradation would deserve further investigation.
In addition, we showed that MART-1 interacts with OA1 early during its biosynthetic pathway acting as an escort protein that helps its stabilization and prevents degradation. Innamorati et al. (5) showed that arrestin induces an accelerated degradation of OA1 in transfected cells, and it is commonly accepted that arrestins can directly induce GPCR degradation by a process distinct from internalization, i.e. by promoting receptor ubiquitination through recruitment of E3 ligases and subsequent lysosomal and/or proteasomalmediated destruction (50, 51) . Future studies are needed to unravel the relationship of OA1 interaction with MART-1, arrestin and perhaps the ESCRT machinery in the regulation of its degradation.
In conclusion, we show that the GPCR OA1 functions in early melanogenesis controlling melanosome size and composition that impact on their identity and consequent maturation. In addition, we evidence that OA1 expression is ensured by its interaction with MART-1, revealing a role for this protein in melanosome biogenesis. Altogether, our data shed light on how OA1 regulates key steps of melanosome formation, also unraveling pathways by which melanosomal proteins are diverted from the classical endocytic organelles and/or differentially targeted to different melanosomal stages. These studies have important implications for understanding the pathophysiology of OA1, the involvement of GPCRs in intracellular trafficking and how highly specialized cells exploit intracellular trafficking pathways to generate unique organelles. Second and importantly, on the basis of the phenotype observed after MART-1 inactivation and its similarity to OA1 loss of function, we suggest that MLANA (the MART-1 gene) is a new candidate gene for albinism. The limited information on MART-1 function, however, does not allow us to define Human Molecular Genetics, 2009, Vol. 18, No. 23 4541 whether MLANA may be a candidate for either ocular albinism or oculocutaneous albinism or syndromic albinism.
MATERIALS AND METHODS
Cell culture, transfection and siRNA depletion
The immortalized Oa1 null (melan-Oa1 2/2 ) and wild-type melanocytic cell lines were derived from wild-type or Oa1 2/2 mouse skin (45) and maintained in RPMI-1640 supplemented with 10% FCS and 200 nM phorbol 12-myristate 13-acetate at 378C with 10% CO 2 . MNT-1 human melanoma cells were maintained as described previously (9) . MNT-1, melan-O and melan-a were transfected with plasmid constructs using Lipofectamine 2000 (Invitrogen) following the manufacturer's recommendations. Cells were collected and analyzed after 48 h. Transfection in MNT-1 with siRNA duplex oligonucleotides proceeded as reported (22) and according to the manufacturer's instructions. Cells were subjected to two rounds of transfection (day 0 and day 2), were passaged as required and processed at day 3 or day 5 for realtime quantitative polymerase chain reaction (qPCR), immunofluorescence microscopy, EM, western blotting and melanin assay. The sense strands for the indicated double-stranded siRNAs (21-mers) were synthesized with the following sequences or derived from the following references. siRNA OA1 1: 5 0 -GGA TAT GAA CCA CAC GGA A-3 0 (Hs_GPR143_6_HP siRNA from Qiagen); siRNA OA1 2: 5 0 -GGC TGT AAA GTA AGT GTA A-3 0 (Hs_GPR143_3_HP siRNA from Qiagen); siRNA OA1 3: 5 0 -GGT TGT CGA ATA TCA TCA A-3 0 (Hs_GPR143_1_HP siRNA from Qiagen); siRNA MART-1 1: 5 0 -AAG ACG AAA TGG ATA CAG AGC-3 0 (26); siRNA MART-1 2: 5 0 -TCC GCT AGC AGT ACT AAT CAT-3 0 (Hs_MLANA_7_HP from Qiagen); siRNA non-targeting control: 5 0 -AAT TCT CCG AAC GTG TCA CGT-3 0 .
Reagents and antibodies
In this study, we used the following primary antibodies: polyclonal anti-human OA1, raised against the C-terminus of the human OA1, similar to that previously published (4); polyclonal anti-EGFP (Molecular Probes); monoclonal anti-flag M2 antibody (Sigma-Aldrich); polyclonal anti-flag (Sigma-Aldrich); monoclonal anti-b-tubulin antibody (Sigma-Aldrich); TA99 mouse anti-Tyrp1 mAb (American Type Culture Collection; (52)) for immunofluoscence and immunogold labeling and monoclonal anti-Tyrp1, 75 kDa (Abcam), for western blotting; melanoma Ab-2 anti-Pmel17 (clone HMB50) (Lab Vision Corporation); mouse monoclonal anti-Pmel17 (clone HMB45) (Novocasta); Pep13h antibody was a kind gift from M.S. Marks (University of Pennsylvania, PA, USA); monoclonal anti-MART-1 7c10 (Abcam); rabbit anti-mouse IgG was purchased from Dakopatt; polyclonal anti-biotin (Polysciences Biovalley); monoclonal anti-LAMP1 (BD Biosciences); chloroquine, MG132 and epoxomycin (Sigma-Aldrich); DAMP (3-(2,4-dinitroanilino)-3 0 ;-amino-N-methyldipropylamine) (Invitrogen); bovine serum albumin coupled to 5 nm gold particles (BSAG) and Protein A Gold conjugates were purchased from Cell Microscopy Center, Utrecht, The Netherlands.
Cloning of OA1-tagged constructs
The human OA1-coding sequence was amplified by PCR by using Pfu high-fidelity DNA polymerase (Promega) and the following primers containing EcoRI and XhoI restriction sites: OA1 forward (fw): CGG AAT TCA TGA CCC AGG CAG GCC GG; OA1 reverse(rw): CCG CTC GAG TCA CAC CTG GAC ACG GAA G. The PCR product was digested by EcoRI and XhoI and subsequently cloned into EcoRI/XhoIdigested pcDNA3-flag vector to express OA1 with a Flag-tag at the C-terminus. The same PCR product was also cloned into pEGFP-N1 vector (Invitrogen) to express OA1 with an EGFP tag at the C-terminus.
Real-time qPCR
Total RNA was extracted from siRNAs and controltransfected MNT-1 cells using RNeasy MiniKit (Qiagen) according to the manufacturer's instructions. The same amount of cDNA was synthesized using Superscript II (Invitrogen) and random primers. Real-time PCR was carried out with the GeneAmp 7000 Sequence Detection System (Applied Biosystem). The RT -PCR reaction was performed using cDNA, 12.5 ml SYBR green master mix (Applied Biosystem) and 400 nM primers for each gene (see the following list). Water was added to a final reaction volume of 25 ml. The PCR conditions were as follows: preheating at 508C for 2 min and 958C for 10 min; 40 cycles of 15 s at 958C and 1 min at 608C.
Quantification results were expressed in terms of the cycle threshold (Ct). All real-time qPCR reactions were run in triplicate, and the Ct values were averaged from three independent samples. Data were normalized to the internal control, the reference gene S26. Differences between the mean Ct values of each gene and those of the reference gene were calculated as DCt ¼ Ct gene 2 Ct reference and represented as 2 2DCt .
Sequences of the fw and rw intron-spanning primers used for real-time qPCRs: Human S26 fw: CCG TGC CTC CAA GAT GAC AA; Human S26 rw: GCA ATG ACG AAT TTC TTA ATG GCC T; Human OA1 fw: CGG AGA TCG GCA GGA CTG AGC AC; Human OA1 rw: ATA GTG GGG GAT GGC GTG GT; Human MART-1 fw: GAA GGG TTT GAT CAT CGG GA; Human MART-1 rw: GCA TTG GGA ACC ACA GGT TC; Human Pmel17-fw: CAG CTC AGC CTT CAC CAT TA; Human Pmel17 rw: AAG TGC TTG TTC CCT CCA TC.
Immunoprecipitations and western blotting
siRNA-treated MNT-1 cells at 80% of confluency and control MNT-1 cells were washed in cold PBS and lysed on ice in lysis buffer [50 mM Tris, 150 mM NaCl, 1% Triton X-100, 10 mM EDTA, pH 7.2, and protease inhibitor cocktail (Roche 11836153001)]. Lysates were then centrifuged at 21 000g for 20 min at 48C. Protein concentrations were determined by Micro BCA TM Protein Assay Reagent Kit (Pierce). The protein samples were mixed with an The separated proteins were then transfered to polyvinylidene difluoride membrane (Millipore) in XCell II TM Blot Module (Invitrogen), and the membranes were blocked in PBS/0.1% Tween-20 (PBS/T) with 5% non-fat dried milk, incubated with primary antibody in PBS/T, washed four times in blocking solution and incubated with horseradish peroxidase-conjugated secondary antibody (anti-rabbit or anti-mouse; 1:10 000; Jackson ImmunoResearch Laboratories) followed by washing in PBS/T. Visualization of the antibody binding was carried out with ECL Plus western blotting detection system (GE Healthcare) according to the manufacturer's instruction. Signal intensities were quantified with ImageJ software.
Melanin assay
Cells were disrupted by sonication in 50 mM Tris-HCl, pH 7.4, 2 mM EDTA, 150 mM NaCl, 1 mM dithiothreitol and protease inhibitors. Pigment was pelleted at 20 000g for 15 min at 48C, rinsed once in ethanol/ether (1:1) and dissolved in 2 M NaOH/ 20% dimethylsulfoxide at 608C. Melanin content was measured as optical density at 492 nm (53) .
Immunofluorescence
Transfected MNT-1 cells on coverslips were rinsed in PBS and fixed for 15 min in 4% paraformaldehyde/PBS at room temperature. Fixed cells were washed in PBS and quenched 10 min in PBS/50 mM glycin, saturated in PBS/1 mg/ml BSA (blocking buffer) and permeabilized in PBS/0.05% saponin/ 1 mg/ml BSA (incubation buffer, IB). Cells were incubated 1 h with the primary antibody diluted in IB, washed three times in IB and incubated with the corresponding secondary antibody Alexa 488-or Alexa 568-conjugated anti-rabbit or anti-mouse secondary antibodies (1:200; Molecular Probes) for 45 min in IB and washed again. Finally, coverslips were mounted in DABCO medium and examined on a Leica Microsystemes (Nanterre, France) DM-RXA2 3D deconvolution microscope equipped with a piezo z-drive (Physik Instrument, Pantin, France) and a 100Â1.4NA-PL-APO objective lens for optical sectioning. Images are maximum-intensity z projections of 3D image stacks acquired using Metamorph software (MDS Analytical Technologies, Sunnyvale, CA, USA) through a Coolsnap HQ (Photometrics Coolsnap HQ) cooled CCD camera, except images shown in Fig 5B -I, where single stacks were deconvoluted.
Electron microscopy
For conventional EM, cells grown on coverslips were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer for 24 h. After several washes with 0.1 M cacodylate buffer, the cells were postfixed with 2% OsO4, dehydrated in ethanol and embedded in Epon while on the coverslips. Ultrathin sections were prepared and counterstained with uranyl acetate and lead citrate before the observation. For quantification, melanosomes were counted on 10 randomly acquired micrographs at X5000 of siOA1 and control MNT-1 cells. The area of cell analyzed was determined by iTEM software and expressed in square micrometers (160 mm 2 ).
For immunogold labelling, cells were fixed with a mixture of 2%PFA and 0.2% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, and processed for ultracryomicrotomy as described previously (54) . Ultrathin cryosections were single-or double-immunogold-labeled with antibodies and protein A coupled to 5 or 10 or 15 nm gold, as indicated in the legends to the figures. Sections of resin-embedded cells and immunogold-labeled cryosections were observed under a Philips CM120 electron microscope (FEI Company), equipped with a KeenView camera (Soft Imaging System; SIS, Germany). For the quantification of OA1 labeling, 500 (endogenous OA1) or 800 gold particles (transfected OA1) were counted in randomly selected cell profiles of cells in each of the two experiments. Tyrp1 and LAMP1 gold particles were randomly counted in a total of 80 unpigmented (stage I/ II) or pigmented (stage III/IV) melanosomes, in two separate experiments. Data are presented as mean + SD.
Uptake of BSAG and DAMP
Uptake of the endocytic tracer BSAG and the weak base DAMP (3-(2,4-dinitroanilino)-3prime;-amino-N-methyldipropylamine) was performed on living cells before fixation and processing as reported previously (9) . For the uptake of BSAG, cells were washed with serum-free DMEM, pulsed for 10 min at 378C with BSAG (OD 520nm ¼ 5), washed with ice-cold medium/2% FBS and the endocytic tracer was chased for 45 min. After washing with ice-cold medium, cells were fixed. For incubation with DAMP, cells were washed with serum-free DMEM and incubated with DAMP (30 mM) for 15 min at 378C. Cells were washed with ice-cold medium and then fixed.
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